Taysha Gene Therapies Inc reports results for the quarter ended June 30 - Earnings Summary

• Taysha Gene Therapies Inc TSHA.OQ reported a quarterly adjusted loss of 9 cents​​ per share for the quarter ended June 30, identical to the same quarter last year. The mean expectation of twelve analysts for the quarter was for a loss of 8 cents per share. Wall Street expected results to range from -9 cents to -7 cents per share.

• Revenue rose 78.6% to $1.99 million from a year ago; analysts expected $1.60 million.

• Taysha Gene Therapies Inc's reported EPS for the quarter was a loss of 9 cents​.

• The company reported a quarterly loss of $26.88 million.

• Taysha Gene Therapies Inc shares had risen by 19.5% this quarter and gained 59.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 8.5% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Taysha Gene Therapies Inc is $8.00, about 65.5% above its last closing price of $2.76

This summary was machine generated from LSEG data August 12 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)